메뉴 건너뛰기




Volumn 23, Issue 8, 2011, Pages 410-420

Role of the nurse practitioner in the management of patients with chronic hepatitis c

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

EID: 79960746772     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2011.00603.x     Document Type: Review
Times cited : (8)

References (68)
  • 1
    • 11144358403 scopus 로고    scopus 로고
    • Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
    • Afdhal, N. H., Dieterich, D. T., Pockros, P. J., Schiff, E. R., Shiffman, M. L., Sulkowski, M. S., Bowers, P. (2004). Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology, 126, 1302-1311.
    • (2004) Gastroenterology , vol.126 , pp. 1302-1311
    • Afdhal, N.H.1    Dieterich, D.T.2    Pockros, P.J.3    Schiff, E.R.4    Shiffman, M.L.5    Sulkowski, M.S.6    Bowers, P.7
  • 2
    • 84857109493 scopus 로고    scopus 로고
    • ® (darbepoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
    • ® (darbepoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
    • (2008)
  • 3
    • 84857109995 scopus 로고    scopus 로고
    • ® (epoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
    • ® (epoetin alfa) for injection. Thousand Oaks, CA: Amgen, Inc.
    • (2008)
  • 4
    • 33748168698 scopus 로고    scopus 로고
    • Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches
    • Asnis, G. M., & De La Garza R II (2006). Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches. Journal of Clinical Gastroenterology, 40, 322-335.
    • (2006) Journal of Clinical Gastroenterology , vol.40 , pp. 322-335
    • Asnis, G.M.1    De La Garza II, R.2
  • 5
    • 66949176133 scopus 로고    scopus 로고
    • Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results
    • Bacon, B. R., Shiffman, M. L., Mendes, F., Ghalib, R., Hassanein, T., Morelli, G., Gitlin, N. (2009). Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology, 49, 1838-1846.
    • (2009) Hepatology , vol.49
    • Bacon, B.R.1    Shiffman, M.L.2    Mendes, F.3    Ghalib, R.4    Hassanein, T.5    Morelli, G.6    Gitlin, N.7
  • 6
    • 33645992473 scopus 로고    scopus 로고
    • Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
    • Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T., Zeuzem, S. (2006). Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology, 130, 1086-1097.
    • (2006) Gastroenterology , vol.130 , pp. 1086-1097
    • Berg, T.1    von Wagner, M.2    Nasser, S.3    Sarrazin, C.4    Heintges, T.5    Gerlach, T.6    Zeuzem, S.7
  • 7
    • 79960719261 scopus 로고    scopus 로고
    • Site and size of interferon pegylation alters affinity to the IFNAR2-extracellular domain. Presented at the 6th International Cytokine Conference, Vienna, Austria.
    • Bordens, R., Xie, L., Wylie, D., Grace, M., & Schreiber, G. (2006). Site and size of interferon pegylation alters affinity to the IFNAR2-extracellular domain. Presented at the 6th International Cytokine Conference, Vienna, Austria.
    • (2006)
    • Bordens, R.1    Xie, L.2    Wylie, D.3    Grace, M.4    Schreiber, G.5
  • 8
    • 10344230440 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial
    • Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Perronne, C. (2004). Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. Journal of the American Medical Association, 292, 2839-2848.
    • (2004) Journal of the American Medical Association , vol.292 , pp. 2839-2848
    • Carrat, F.1    Bani-Sadr, F.2    Pol, S.3    Rosenthal, E.4    Lunel-Fabiani, F.5    Benzekri, A.6    Perronne, C.7
  • 9
    • 0013690671 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Retrieved March 28, 2008, from
    • Centers for Disease Control and Prevention. (2008). Hepatitis C fact sheet. Centers for Disease Control and Prevention. Retrieved March 28, 2008, from
    • (2008) Hepatitis C fact sheet
  • 10
    • 33646270395 scopus 로고    scopus 로고
    • Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease
    • Chevaliez, S., & Pawlotsky, J.-M. (2006). Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. International Journal of Medical Sciences, 3, 35-40.
    • (2006) International Journal of Medical Sciences , vol.3 , pp. 35-40
    • Chevaliez, S.1    Pawlotsky, J.-M.2
  • 12
    • 11144252779 scopus 로고    scopus 로고
    • The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin
    • Collantes, R. S., & Younossi, Z. M. (2005). The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. Journal of Clinical Gastroenterology, 39, S9-S13.
    • (2005) Journal of Clinical Gastroenterology , vol.39
    • Collantes, R.S.1    Younossi, Z.M.2
  • 13
    • 33845641280 scopus 로고    scopus 로고
    • Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy
    • Del Rio, R. A., Post, A. B., & Singer, M. E. (2006). Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology, 44, 1598-1606.
    • (2006) Hepatology , vol.44 , pp. 1598-1606
    • Del Rio, R.A.1    Post, A.B.2    Singer, M.E.3
  • 14
    • 30044432484 scopus 로고    scopus 로고
    • American gastroenterological association technical review on the management of hepatitis C
    • Dienstag, J. L., & McHutchison, J. G. (2006). American gastroenterological association technical review on the management of hepatitis C. Gastroenterology, 130, 231-264.
    • (2006) Gastroenterology , vol.130 , pp. 231-264
    • Dienstag, J.L.1    McHutchison, J.G.2
  • 15
    • 0242437747 scopus 로고    scopus 로고
    • Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa
    • Dieterich, D. T., Wasserman, R., Brau, N., Hassanein, T. I., Bini, E. J., Bowers, P. J., and Sulkowski, M.S. (2003). Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology, 98, 2491-2499.
    • (2003) American Journal of Gastroenterology , vol.98 , pp. 2491-2499
    • Dieterich, D.T.1    Wasserman, R.2    Brau, N.3    Hassanein, T.I.4    Bini, E.J.5    Bowers, P.J.6    Sulkowski, M.S.7
  • 16
    • 33845645008 scopus 로고    scopus 로고
    • Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    • Everson, G. T., Hoefs, J. C., Seeff, L. B., Bonkovsky, H. L., Naishadham, D., Shiffman, M. L., Morishima, C. (2006). Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology, 44, 1675-1684.
    • (2006) Hepatology , vol.44 , pp. 1675-1684
    • Everson, G.T.1    Hoefs, J.C.2    Seeff, L.B.3    Bonkovsky, H.L.4    Naishadham, D.5    Shiffman, M.L.6    Morishima, C.7
  • 17
    • 48749099989 scopus 로고    scopus 로고
    • Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    • Ferenci, P., Laferl, H., Scherzer, T. M., Gschwantler, M., Maieron, A., Brunner, H., Steindl-Munda, P. (2008). Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology, 135, 451-458.
    • (2008) Gastroenterology , vol.135 , pp. 451-458
    • Ferenci, P.1    Laferl, H.2    Scherzer, T.M.3    Gschwantler, M.4    Maieron, A.5    Brunner, H.6    Steindl-Munda, P.7
  • 19
    • 0036830454 scopus 로고    scopus 로고
    • Side effects of therapy of hepatitis C and their management
    • Fried, M. W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36, S237-S244.
    • (2002) Hepatology , vol.36
    • Fried, M.W.1
  • 21
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: An update
    • Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49, 1335-1374.
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3    Seeff, L.B.4
  • 22
    • 20044385757 scopus 로고    scopus 로고
    • Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway
    • Grace, M. J., Lee, S., Bradshaw, S., Chapman, J., Spond, J., Cox, S., Bordens, R. (2005). Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. Journal of Biological Chemistry, 280, 6327-6336.
    • (2005) Journal of Biological Chemistry , vol.280 , pp. 6327-6336
    • Grace, M.J.1    Lee, S.2    Bradshaw, S.3    Chapman, J.4    Spond, J.5    Cox, S.6    Bordens, R.7
  • 23
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
    • Hadziyannis, S. J., Sette, H. Jr., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ackrill, A.M. (2004). Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140, 346-355.
    • (2004) Annals of Internal Medicine , vol.140 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr, H.2    Morgan, T.R.3    Balan, V.4    Diago, M.5    Marcellin, P.6    Ackrill, A.M.7
  • 24
    • 0036430340 scopus 로고    scopus 로고
    • A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C
    • Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Howell, C.D. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry, 7, 942-947.
    • (2002) Molecular Psychiatry , vol.7 , pp. 942-947
    • Hauser, P.1    Khosla, J.2    Aurora, H.3    Laurin, J.4    Kling, M.A.5    Hill, J.6    Howell, C.D.7
  • 26
    • 79959749091 scopus 로고    scopus 로고
    • Hoffman La Roche, Nutley, NJ: Hoffman-La Roche, Inc.
    • Hoffman La Roche, Inc. (2008). Pegasys (peginterferon alfa-2a). Nutley, NJ: Hoffman-La Roche, Inc.
    • (2008) Pegasys (peginterferon alfa-2a)
  • 27
    • 0036828784 scopus 로고    scopus 로고
    • The burden of hepatitis C in the United States
    • Kim, W. R. (2002). The burden of hepatitis C in the United States. Hepatology, 36, S30-S34.
    • (2002) Hepatology , vol.36
    • Kim, W.R.1
  • 28
    • 13244249842 scopus 로고    scopus 로고
    • Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression
    • Kraus, M. R., Schafer, A., Al-Taie, O., & Scheurlen, M. (2005). Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. Journal of Viral Hepatitis, 12, 96-100.
    • (2005) Journal of Viral Hepatitis , vol.12 , pp. 96-100
    • Kraus, M.R.1    Schafer, A.2    Al-Taie, O.3    Scheurlen, M.4
  • 30
    • 84857109999 scopus 로고    scopus 로고
    • Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron™ (peginterferon alfa-2b)/Ribavirin in treatment-naïve subject with genotype-1 CHC [abstract]. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
    • Kwo, P., Lawitz, E., McCone, J., Schiff, E., Vierling, J., Pound, D., Albrecht, J.K. (2008). Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron™ (peginterferon alfa-2b)/Ribavirin in treatment-naïve subject with genotype-1 CHC [abstract]. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
    • (2008)
    • Kwo, P.1    Lawitz, E.2    McCone, J.3    Schiff, E.4    Vierling, J.5    Pound, D.6    Albrecht, J.K.7
  • 31
    • 59149085501 scopus 로고    scopus 로고
    • The global burden of hepatitis C
    • Lavanchy, D. (2009). The global burden of hepatitis C. Liver International, 29, 74-81.
    • (2009) Liver International , vol.29 , pp. 74-81
    • Lavanchy, D.1
  • 32
    • 67650558336 scopus 로고    scopus 로고
    • Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-RIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin
    • Lawitz, E. J., Zaman, A., Muir, A. J., Shiffman, M. L., Yoffe, B., Zhang, T., Hausman, D.F. (2008). Interim results from a phase 1b dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-RIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin. Hepatology 48, 385A.
    • (2008) Hepatology , vol.48
    • Lawitz, E.J.1    Zaman, A.2    Muir, A.J.3    Shiffman, M.L.4    Yoffe, B.5    Zhang, T.6    Hausman, D.F.7
  • 33
    • 44449146437 scopus 로고    scopus 로고
    • Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin
    • Leevy, C. B. (2008). Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Digestive Diseases and Sciences, 53, 1961-1966.
    • (2008) Digestive Diseases and Sciences , vol.53 , pp. 1961-1966
    • Leevy, C.B.1
  • 34
    • 2442425456 scopus 로고    scopus 로고
    • Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-α: A prospective case series and a discussion of biological mechanisms
    • Maddock, C., Baita, A., Orru, M. G., Sitzia, R., Costa, A., Muntoni, E., ... Pariante, C.M. (2004). Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-α: A prospective case series and a discussion of biological mechanisms. Journal of Psychopharmacology, 18, 41-46.
    • (2004) Journal of Psychopharmacology , vol.18 , pp. 41-46
    • Maddock, C.1    Baita, A.2    Orru, M.G.3    Sitzia, R.4    Costa, A.5    Muntoni, E.6    Pariante, C.M.7
  • 35
    • 16844368692 scopus 로고    scopus 로고
    • Psychopathological symptoms during interferon-α and ribavirin treatment: Effects on virologic response
    • Maddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., ... Pariante, C.M. (2005). Psychopathological symptoms during interferon-α and ribavirin treatment: Effects on virologic response. Molecular Psychiatry, 10, 332-333.
    • (2005) Molecular Psychiatry , vol.10 , pp. 332-333
    • Maddock, C.1    Landau, S.2    Barry, K.3    Maulayah, P.4    Hotopf, M.5    Cleare, A.J.6    Pariante, C.M.7
  • 36
    • 38649090347 scopus 로고    scopus 로고
    • Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    • Mangia, A., Minerva, N., Bacca, D., Cozzolongo, R., Ricci, G. L., Carretta, V., ... Andriulli, A. (2008). Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology, 47, 43-50.
    • (2008) Hepatology , vol.47 , pp. 43-50
    • Mangia, A.1    Minerva, N.2    Bacca, D.3    Cozzolongo, R.4    Ricci, G.L.5    Carretta, V.6    Andriulli, A.7
  • 38
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., ... Albrecht, J.K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958-965.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3    Rustgi, V.K.4    Shiffman, M.5    Reindollar, R.6    Albrecht, J.K.7
  • 40
    • 30344436353 scopus 로고    scopus 로고
    • The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice
    • McHutchison, J. G., Bartenschlager, R., Patel, K., & Pawlotsky, J.-M. (2006). The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice. Journal of Hepatology, 44, 411-421.
    • (2006) Journal of Hepatology , vol.44 , pp. 411-421
    • McHutchison, J.G.1    Bartenschlager, R.2    Patel, K.3    Pawlotsky, J.-M.4
  • 43
    • 0036788338 scopus 로고    scopus 로고
    • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    • McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., ... Albrecht, J.K. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123, 1061-1069.
    • (2002) Gastroenterology , vol.123 , pp. 1061-1069
    • McHutchison, J.G.1    Manns, M.2    Patel, K.3    Poynard, T.4    Lindsay, K.L.5    Trepo, C.6    Albrecht, J.K.7
  • 44
    • 2442665224 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
    • amp; the Atlantic Coast Hepatitis Treatment Group.
    • Muir, A. J., Bornstein, J. D., Killenberg, P. G., & the Atlantic Coast Hepatitis Treatment Group. (2004). Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine, 350, 2265-2271.
    • (2004) New England Journal of Medicine , vol.350 , pp. 2265-2271
    • Muir, A.J.1    Bornstein, J.D.2    Killenberg, P.G.3
  • 45
    • 33845616297 scopus 로고    scopus 로고
    • Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
    • Muir, A. J., & McHutchison, J. G. (2006). Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology, 44, 1400-1403.
    • (2006) Hepatology , vol.44 , pp. 1400-1403
    • Muir, A.J.1    McHutchison, J.G.2
  • 46
    • 79960738740 scopus 로고    scopus 로고
    • The use of growth factors (GF) in the re-treatment of patients with chronic hepatitis C (CHC) who are previous non responders (NR) to combination therapy. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain.
    • Nader, F., Bai, C., Terra, K., Gurung, C., Srishord, M., Fang, Y., ... Younossi, Z. M. (2007). The use of growth factors (GF) in the re-treatment of patients with chronic hepatitis C (CHC) who are previous non responders (NR) to combination therapy. Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain.
    • (2007)
    • Nader, F.1    Bai, C.2    Terra, K.3    Gurung, C.4    Srishord, M.5    Fang, Y.6    Younossi, Z.M.7
  • 47
    • 66849088067 scopus 로고    scopus 로고
    • National Institute of Diabetes and Digestive and Kidney Diseases. (). National Digestive Diseases Information Clearinghouse. Retrieved March 16, 2009, from
    • National Institute of Diabetes and Digestive and Kidney Diseases. (2006). Chronic hepatitis C: current disease management. National Digestive Diseases Information Clearinghouse. Retrieved March 16, 2009, from
    • (2006) Chronic hepatitis C: current disease management
  • 48
    • 6044253416 scopus 로고    scopus 로고
    • Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia
    • Ong, J. P., & Younossi, Z. M. (2004). Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia. Cleveland Clinic Journal of Medicine, 71, S17-S21.
    • (2004) Cleveland Clinic Journal of Medicine , vol.71
    • Ong, J.P.1    Younossi, Z.M.2
  • 49
    • 37749051824 scopus 로고    scopus 로고
    • Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders
    • Pearlman, B. L., Ehleben, C., & Saifee, S. (2007). Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology, 46, 1688-1694.
    • (2007) Hepatology , vol.46 , pp. 1688-1694
    • Pearlman, B.L.1    Ehleben, C.2    Saifee, S.3
  • 53
    • 79960707083 scopus 로고    scopus 로고
    • Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day. Poster presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA.
    • Reau, N., Jensen, D., Hadziyannis, S., Messinger, D., & Fried, M. (2006). Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day. Poster presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA.
    • (2006)
    • Reau, N.1    Jensen, D.2    Hadziyannis, S.3    Messinger, D.4    Fried, M.5
  • 56
    • 0037308288 scopus 로고    scopus 로고
    • Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups
    • Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., ... Loeschke, K. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 37, 443-451.
    • (2003) Hepatology , vol.37 , pp. 443-451
    • Schaefer, M.1    Schmidt, F.2    Folwaczny, C.3    Lorenz, R.4    Martin, G.5    Schindlbeck, N.6    Loeschke, K.7
  • 58
    • 77952244103 scopus 로고    scopus 로고
    • Schering Corporation. Kenilworth, NJ: Schering Corporation.
    • Schering Corporation. (2009). PegIntron (peginterferon alfa-2b) injection. Kenilworth, NJ: Schering Corporation.
    • (2009) PegIntron (peginterferon alfa-2b) injection
  • 59
    • 79960713753 scopus 로고    scopus 로고
    • Boceprevir (NS3 protease inhibitor) combination therapy in non responders: Phase II dose finding study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
    • Schiff, E., Poordad, F., Jacobson, I., Flamm, S., Bacon, B., Lawitz, E., ... Albrecht, J.K. (2008). Boceprevir (NS3 protease inhibitor) combination therapy in non responders: Phase II dose finding study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy.
    • (2008)
    • Schiff, E.1    Poordad, F.2    Jacobson, I.3    Flamm, S.4    Bacon, B.5    Lawitz, E.6    Albrecht, J.K.7
  • 61
    • 33745713376 scopus 로고    scopus 로고
    • A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
    • Silva, M., Poo, J., Wagner, F., Jackson, M., Cutler, D., Grace, M., ... Laughlin, M. (2006). A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology, 45, 204-213.
    • (2006) Journal of Hepatology , vol.45 , pp. 204-213
    • Silva, M.1    Poo, J.2    Wagner, F.3    Jackson, M.4    Cutler, D.5    Grace, M.6    Laughlin, M.7
  • 62
    • 1842479859 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C
    • Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147-1171.
    • (2004) Hepatology , vol.39 , pp. 1147-1171
    • Strader, D.B.1    Wright, T.2    Thomas, D.L.3    Seeff, L.B.4
  • 64
    • 23244457832 scopus 로고    scopus 로고
    • Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
    • von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T., ... Zeuzem, S. (2005). Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129, 522-527.
    • (2005) Gastroenterology , vol.129 , pp. 522-527
    • von Wagner, M.1    Huber, M.2    Berg, T.3    Hinrichsen, H.4    Rasenack, J.5    Heintges, T.6    Zeuzem, S.7
  • 66
    • 41549162418 scopus 로고    scopus 로고
    • A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment
    • Younossi, Z. M., Nader, F. H., Bai, C., Sjogren, R., Ong, J. P., Collantes, R., ... Fang, Y. (2008). A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. Journal of Viral Hepatitis, 15, 370-378.
    • (2008) Journal of Viral Hepatitis , vol.15 , pp. 370-378
    • Younossi, Z.M.1    Nader, F.H.2    Bai, C.3    Sjogren, R.4    Ong, J.P.5    Collantes, R.6    Fang, Y.7
  • 67
    • 28844451934 scopus 로고    scopus 로고
    • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    • Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., ... Albrecht, J.K. (2006). Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 44, 97-103.
    • (2006) Journal of Hepatology , vol.44 , pp. 97-103
    • Zeuzem, S.1    Buti, M.2    Ferenci, P.3    Sperl, J.4    Horsmans, Y.5    Cianciara, J.6    Albrecht, J.K.7
  • 68
    • 3042679031 scopus 로고    scopus 로고
    • Dynamics of hepatitis C virus infection
    • Zeuzem, S., & Herrmann, E. (2002). Dynamics of hepatitis C virus infection. Annals of Hepatology, 1, 56-63.
    • (2002) Annals of Hepatology , vol.1 , pp. 56-63
    • Zeuzem, S.1    Herrmann, E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.